Welcome to our dedicated page for Alumis SEC filings (Ticker: ALMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
Alumis Inc. filed a current report stating that it issued a press release on November 13, 2025, to announce its financial results for the fiscal quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and provides details on the company’s operations and financial condition for the period.
The company also identifies Exhibit 104 as the cover page interactive data file embedded within the Inline XBRL document. The report is signed by Martin Babler, President and Chief Executive Officer of Alumis Inc.
Alumis Inc. filed a current report to note that it has updated its corporate presentation for use in meetings with investors, analysts, and other audiences as of September 2025. The updated presentation is included as Exhibit 99.1 to the report on Form 8-K.
The company states that the information in the report and the attached presentation is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and will not automatically be incorporated by reference into other securities law filings unless specifically referenced.
Alumis Inc. completed the ACELYRIN merger and significantly strengthened its balance sheet. Total assets rose to $610.9 million from $341.0 million at year-end, and combined cash, cash equivalents and marketable securities totaled approximately $486.3 million as of June 30, 2025. The company issued 48,653,549 shares (about $238.1 million consideration) to acquire ACELYRIN, adding the lonigutamab program and an IPR&D intangible asset valued at ~$51.0 million. The acquisition produced a $187.9 million gain on bargain purchase, which turned the quarter to a $59.3 million net income result.
Operationally Alumis remains a development-stage, cash-consuming biopharma. Revenue was $2.7 million for the quarter ($20.1 million six months) while research and development expense rose to $108.8 million in the quarter and operating cash used was $186.7 million for the six months. The company had an accumulated deficit of $698.2 million and states existing resources should fund operations for at least 12 months, though additional capital will be needed thereafter.
Alumis Inc. furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Form 8-K. The filing states that the information in Item 2.02 and Exhibit 99.1 is furnished and therefore is not deemed to be "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The report is signed by Martin Babler, President and Chief Executive Officer.